PH24502A - Indene analogs of mevalonolactone and derivatives thereof - Google Patents

Indene analogs of mevalonolactone and derivatives thereof

Info

Publication number
PH24502A
PH24502A PH33123A PH33123A PH24502A PH 24502 A PH24502 A PH 24502A PH 33123 A PH33123 A PH 33123A PH 33123 A PH33123 A PH 33123A PH 24502 A PH24502 A PH 24502A
Authority
PH
Philippines
Prior art keywords
6alkyl
hydrogen
3alkyl
benzyloxy
phenoxy
Prior art date
Application number
PH33123A
Other languages
English (en)
Inventor
Faizulla G Kathawala
Sompong Wattanasin
Original Assignee
Sandoz Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz Pharmaceuticals Corp filed Critical Sandoz Pharmaceuticals Corp
Publication of PH24502A publication Critical patent/PH24502A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/738—Esters of keto-carboxylic acids or aldehydo-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30—Oxygen atoms, e.g. delta-lactones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C17/00—Preparation of halogenated hydrocarbons
    • C07C17/26—Preparation of halogenated hydrocarbons by reactions involving an increase in the number of carbon atoms in the skeleton
    • C07C17/263—Preparation of halogenated hydrocarbons by reactions involving an increase in the number of carbon atoms in the skeleton by condensation reactions
    • C07C17/2632—Preparation of halogenated hydrocarbons by reactions involving an increase in the number of carbon atoms in the skeleton by condensation reactions involving an organo-magnesium compound, e.g. Grignard synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/20—Unsaturated compounds having —CHO groups bound to acyclic carbon atoms
    • C07C47/24—Unsaturated compounds having —CHO groups bound to acyclic carbon atoms containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/52—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
    • C07C47/56—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing hydroxy groups
    • C07C47/57—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing hydroxy groups polycyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/732—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids of unsaturated hydroxy carboxylic acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Manufacture Of Tobacco Products (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Furan Compounds (AREA)
PH33123A 1984-12-04 1985-12-03 Indene analogs of mevalonolactone and derivatives thereof PH24502A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US67791784A 1984-12-04 1984-12-04

Publications (1)

Publication Number Publication Date
PH24502A true PH24502A (en) 1990-07-18

Family

ID=24720627

Family Applications (1)

Application Number Title Priority Date Filing Date
PH33123A PH24502A (en) 1984-12-04 1985-12-03 Indene analogs of mevalonolactone and derivatives thereof

Country Status (19)

Country Link
EP (1) EP0216785B1 (fr)
JP (1) JPS62501009A (fr)
KR (1) KR910003427B1 (fr)
AT (1) ATE60571T1 (fr)
AU (1) AU599580B2 (fr)
DE (1) DE3581638D1 (fr)
DK (1) DK369086A (fr)
ES (1) ES8800888A1 (fr)
FI (1) FI863121A (fr)
GR (1) GR852895B (fr)
HU (1) HU198005B (fr)
IL (1) IL77199A (fr)
MY (1) MY100972A (fr)
NZ (1) NZ214402A (fr)
PH (1) PH24502A (fr)
PL (1) PL147645B1 (fr)
PT (1) PT81603B (fr)
WO (1) WO1986003488A1 (fr)
ZA (1) ZA859303B (fr)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5001255A (en) * 1984-12-04 1991-03-19 Sandoz Pharm. Corp. Idene analogs of mevalonolactone and derivatives thereof
HUT48208A (en) * 1985-10-25 1989-05-29 Sandoz Ag Process for producing heterocyclic analogues of mevalolactone derivatives and pharmaceutical compositions comprising such compounds
US4751235A (en) * 1986-12-23 1988-06-14 Sandoz Pharm. Corp. Anti-atherosclerotic indolizine derivatives
US5091378A (en) * 1987-05-22 1992-02-25 E. R. Squibb & Sons, Inc. Phosphorus-containing HMG-CoA reductase inhibitors, new intermediates and method
US4904691A (en) * 1987-12-21 1990-02-27 Rorer Pharmaceutical Corporation Novel HMG-CoA reductase inhibitors
US4822799A (en) * 1988-01-27 1989-04-18 Sandoz Pharm. Corp. Pyrazolopyridine analogs of mevalonolactone and derivatives thereof useful for inhibiting cholesterol biosynthesis in mammals
US4876280A (en) * 1988-03-10 1989-10-24 Sandoz Pharm. Corp. Arylcyclohexane and arylcyclohexene analogs of mevalonolactone derivatives and their use
US5506219A (en) * 1988-08-29 1996-04-09 E. R. Squibb & Sons, Inc. Pyridine anchors for HMG-CoA reductase inhibitors
EP0562643A3 (en) * 1988-10-13 1994-05-18 Sandoz Ag 7-substituted-hept-6-enoic and -heptanoic acids and derivatives thereof
FR2642065B1 (fr) * 1989-01-24 1991-05-24 Lipha Derives d'acides benzocycloalcenyl dihydroxy alcanoiques, procede de preparation et medicaments les contenant
US5025017A (en) * 1989-09-28 1991-06-18 E. R. Squibb & Sons, Inc. Seco-mevinic acid derivatives useful as antihypercholesterolemic agents and new intermediates
US5189180A (en) * 1989-09-28 1993-02-23 E. R. Squibb & Sons, Inc. Seco-mevinic acid derivatives useful as antihypercholesterolemic agents and new intermediates
JPH03173882A (ja) * 1989-09-29 1991-07-29 Tanabe Seiyaku Co Ltd クロメン又はチオクロメン誘導体、その製法及びその合成中間体
WO1992019240A1 (fr) * 1991-05-01 1992-11-12 University Of New Mexico Traitement d'aberrations cellulaires avec des biomodulateurs
WO1992019239A1 (fr) * 1991-05-01 1992-11-12 University Of New Mexico Traitement d'etats cellulaires aberrants a l'aide de biomodulateurs
US5256692A (en) * 1992-01-07 1993-10-26 E. R. Squibb & Sons, Inc. Sulfur-containing HMG-COA reductase inhibitors
US20010006644A1 (en) 1997-07-31 2001-07-05 David J. Bova Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night
US7276249B2 (en) 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
ES2258141T3 (es) 2001-04-11 2006-08-16 Bristol-Myers Squibb Company Complejos de aminoacidos de glucosidos c-arilo para el tratamiento de la diabetes y procedimiento.
IL160917A0 (en) 2001-10-18 2004-08-31 Bristol Myers Squibb Co Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
US7238671B2 (en) 2001-10-18 2007-07-03 Bristol-Myers Squibb Company Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
US6806381B2 (en) 2001-11-02 2004-10-19 Bristol-Myers Squibb Company Process for the preparation of aniline-derived thyroid receptor ligands
EP1443919A4 (fr) 2001-11-16 2006-03-22 Bristol Myers Squibb Co Inhibiteurs doubles de la proteine de liaison des acides gras des adipocytes et de la proteine de liaison des acides gras des keratinocytes
US6831102B2 (en) 2001-12-07 2004-12-14 Bristol-Myers Squibb Company Phenyl naphthol ligands for thyroid hormone receptor
US6747048B2 (en) 2002-05-08 2004-06-08 Bristol-Myers Squibb Company Pyridine-based thyroid receptor ligands
US7057046B2 (en) 2002-05-20 2006-06-06 Bristol-Myers Squibb Company Lactam glycogen phosphorylase inhibitors and method of use
AU2003241477A1 (en) 2002-06-10 2003-12-22 Elan Pharma International, Ltd. Nanoparticulate polycosanol formulations and novel polycosanol combinations
WO2004037181A2 (fr) 2002-10-23 2004-05-06 Bristol-Myers Squibb Company Inhibiteurs de dipeptidyl peptidase iv a base de glycinenitrile et procedes correspondants
US7098235B2 (en) 2002-11-14 2006-08-29 Bristol-Myers Squibb Co. Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
DE60323536D1 (de) 2002-12-20 2008-10-23 Pfizer Prod Inc Dosierungsform enthaltend einen cetp-hemmer und einen hmg-coa reduktase hemmer
TW200504021A (en) 2003-01-24 2005-02-01 Bristol Myers Squibb Co Substituted anilide ligands for the thyroid receptor
US7557143B2 (en) 2003-04-18 2009-07-07 Bristol-Myers Squibb Company Thyroid receptor ligands
US7459474B2 (en) 2003-06-11 2008-12-02 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor and method
US6995183B2 (en) 2003-08-01 2006-02-07 Bristol Myers Squibb Company Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
EP2428516A1 (fr) 2003-11-19 2012-03-14 Metabasis Therapeutics, Inc. Nouvelles substances thyromimetiques contenant du phosphore
JP5697296B2 (ja) 2004-03-05 2015-04-08 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 高脂血症および高コレステロール血症に関連する障害または疾患を、副作用を最小限にしつつ処置するための方法
US7534763B2 (en) 2004-07-02 2009-05-19 Bristol-Myers Squibb Company Sustained release GLP-1 receptor modulators
TW200611704A (en) 2004-07-02 2006-04-16 Bristol Myers Squibb Co Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
US7145040B2 (en) 2004-07-02 2006-12-05 Bristol-Myers Squibb Co. Process for the preparation of amino acids useful in the preparation of peptide receptor modulators
AR051446A1 (es) 2004-09-23 2007-01-17 Bristol Myers Squibb Co Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
US7517991B2 (en) 2004-10-12 2009-04-14 Bristol-Myers Squibb Company N-sulfonylpiperidine cannabinoid receptor 1 antagonists
US7589088B2 (en) 2004-12-29 2009-09-15 Bristol-Myers Squibb Company Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
US7635699B2 (en) 2004-12-29 2009-12-22 Bristol-Myers Squibb Company Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
WO2006076568A2 (fr) 2005-01-12 2006-07-20 Bristol-Myers Squibb Company Heterocycles bicycliques servant de modulateurs au recepteur de cannabinoides
WO2006076597A1 (fr) 2005-01-12 2006-07-20 Bristol-Myers Squibb Company Heterocycles bicycliques constituant des modulateurs des recepteurs cannabinoides
US7314882B2 (en) 2005-01-12 2008-01-01 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
WO2006078697A1 (fr) 2005-01-18 2006-07-27 Bristol-Myers Squibb Company Heterocycles bicycliques utilises comme modulateurs des recepteurs de cannabinoide
EP2527337A1 (fr) 2005-04-14 2012-11-28 Bristol-Myers Squibb Company Inhibiteurs de la 11-bêta hydroxystéroïde déshydrogénase de type I
US7521557B2 (en) 2005-05-20 2009-04-21 Bristol-Myers Squibb Company Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods
US7629342B2 (en) 2005-06-17 2009-12-08 Bristol-Myers Squibb Company Azabicyclic heterocycles as cannabinoid receptor modulators
US7317012B2 (en) 2005-06-17 2008-01-08 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoind-1 receptor modulators
US7572808B2 (en) 2005-06-17 2009-08-11 Bristol-Myers Squibb Company Triazolopyridine cannabinoid receptor 1 antagonists
US7452892B2 (en) 2005-06-17 2008-11-18 Bristol-Myers Squibb Company Triazolopyrimidine cannabinoid receptor 1 antagonists
US7632837B2 (en) 2005-06-17 2009-12-15 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid-1 receptor modulators
US8618115B2 (en) 2005-10-26 2013-12-31 Bristol-Myers Squibb Company Substituted thieno[3,2-d]pyrimidinones as MCHR1 antagonists and methods for using them
US7488725B2 (en) 2005-10-31 2009-02-10 Bristol-Myers Squibb Co. Pyrrolidinyl beta-amino amide-based inhibitors of dipeptidyl peptidase IV and methods
US7592461B2 (en) 2005-12-21 2009-09-22 Bristol-Myers Squibb Company Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7553836B2 (en) 2006-02-06 2009-06-30 Bristol-Myers Squibb Company Melanin concentrating hormone receptor-1 antagonists
US8367112B2 (en) 2006-02-28 2013-02-05 Alkermes Pharma Ireland Limited Nanoparticulate carverdilol formulations
WO2007139589A1 (fr) 2006-05-26 2007-12-06 Bristol-Myers Squibb Company Modulateurs des récepteurs de glp-1 à libération prolongée
US7919598B2 (en) 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
US7795291B2 (en) 2006-07-07 2010-09-14 Bristol-Myers Squibb Company Substituted acid derivatives useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic and anti-obesity agents and method
EP2089355A2 (fr) 2006-11-01 2009-08-19 Brystol-Myers Squibb Company Modulateurs de recepteur de glucocorticoide, d'activite ap-1 et/ou nf- kappa b, et leur utilisation
AR065809A1 (es) 2007-03-22 2009-07-01 Bristol Myers Squibb Co Formulaciones farmaceuticas que contienen un inhibidor sglt2
PE20090696A1 (es) 2007-04-20 2009-06-20 Bristol Myers Squibb Co Formas cristalinas de saxagliptina y procesos para preparar las mismas
CA2687964A1 (fr) 2007-06-01 2009-02-19 The Trustees Of Princeton University Traitement d'infections virales par modulation de voies metaboliques de cellules hotes
US20090011994A1 (en) 2007-07-06 2009-01-08 Bristol-Myers Squibb Company Non-basic melanin concentrating hormone receptor-1 antagonists and methods
JP2010534722A (ja) 2007-07-27 2010-11-11 ブリストル−マイヤーズ スクイブ カンパニー 新規グルコキナーゼ活性化薬およびその使用方法
CA2697551C (fr) 2007-09-20 2013-03-12 Irm Llc Composes et compositions en tant que modulateurs de l'activite de gpr119
EP2209780B1 (fr) 2007-11-01 2014-01-01 Bristol-Myers Squibb Company Composes non steroïdiens utiles en tant que modulateurs de l'activite ap-1 et/ou nf- b du recepteur des glucocorticoïdes et leur utilisation
PE20091928A1 (es) 2008-05-29 2009-12-31 Bristol Myers Squibb Co Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos
WO2010093601A1 (fr) 2009-02-10 2010-08-19 Metabasis Therapeutics, Inc. Nouveaux thyromimetiques contenant de l'acide sulfonique et methodes d'utilisation associees
SG174504A1 (en) 2009-03-27 2011-10-28 Bristol Myers Squibb Co Methods for preventing major adverse cardiovascular events with dpp-iv inhibitors
WO2011014520A2 (fr) 2009-07-29 2011-02-03 Irm Llc Composés et compositions pouvant servir de modulateurs de l'activité du gpr119
MX2012004078A (es) 2009-10-09 2012-07-25 Irm Llc Compuestos y composiciones como moduladores de la actividad de gpr119.
US20120294936A1 (en) 2009-11-13 2012-11-22 Astrazeneca Uk Limited Reduced mass metformin formulations
CA2780939C (fr) 2009-11-13 2018-06-12 Bristol-Myers Squibb Company Formulations de comprime bicouche
AU2010319377B2 (en) 2009-11-13 2014-10-23 Astrazeneca Ab Immediate release tablet formulations
US8394858B2 (en) 2009-12-03 2013-03-12 Novartis Ag Cyclohexane derivatives and uses thereof
TWI562775B (en) 2010-03-02 2016-12-21 Lexicon Pharmaceuticals Inc Methods of using inhibitors of sodium-glucose cotransporters 1 and 2
CN102971313A (zh) 2010-04-14 2013-03-13 百时美施贵宝公司 新颖的葡糖激酶激活剂及其使用方法
WO2012006398A2 (fr) 2010-07-09 2012-01-12 Bhv Pharma, Inc. Système d'administration à libération immédiate/retardée en combinaison pour des médicaments à courte demi-vie comprenant de la rémogliflozine
US8697739B2 (en) 2010-07-29 2014-04-15 Novartis Ag Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof
TWI631963B (zh) 2011-01-05 2018-08-11 雷西肯製藥股份有限公司 包含鈉－葡萄糖共同輸送體１與２之抑制劑的組合物與應用方法
WO2014052619A1 (fr) 2012-09-27 2014-04-03 Irm Llc Dérivés et compositions de pipéridine comme modulateurs de l'activité de gpr119
DK3489226T3 (da) 2012-11-20 2021-04-26 Lexicon Pharmaceuticals Inc Hæmmere for natriumglucose-cotransporter 1
AR094054A1 (es) * 2012-12-19 2015-07-08 H Lundbeck As 6-cloro-3-(fenil-d₅)-inden-1-ona y uso de la misma
US9593113B2 (en) 2013-08-22 2017-03-14 Bristol-Myers Squibb Company Imide and acylurea derivatives as modulators of the glucocorticoid receptor
WO2016176656A2 (fr) 2015-04-30 2016-11-03 President And Fellows Of Harvard College Anticorps anti-ap2 et agents de liaison à l'antigène utilisables en vue du traitement d'affections métaboliques
MX2021000601A (es) 2018-07-19 2021-04-13 Astrazeneca Ab Metodos de tratamiento de hfpef empleando dapagliflozina y composiciones que comprenden la misma.
SG11202102498UA (en) 2018-09-26 2021-04-29 Lexicon Pharmaceuticals Inc Crystalline forms of n-(1 -((2-(dimethylamino)ethyl)amino)-2-m ethyl-1 -oopropan-2-yl)-4-(4-(2-methyl-5- (2s,3r,4r,5s,6r)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2h-pyran-2-yl)benzyl) phenl)butanamide and methods of their synthesis
EP3891134A1 (fr) 2018-12-03 2021-10-13 H. Lundbeck A/S Promédicaments de 4-((1r,3s)-6-chloro-3-phényl-2,3-dihydro-1h-inden-1-yl)-1,2,2-triméthylpipérazine et 4-((1/r,3s)-6-chloro-3-(phényl-d5)-2,3-dihydro-1h-inden-1-yl)-2,2-diméthy-1-(méthyl-d3)pipérazine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5559140A (en) * 1978-10-30 1980-05-02 Sankyo Co Ltd 3,5-dihydroxypentanoic alkyl ester derivative, its preparation and remedy for hyperlipemia containing the same as the effective component
AU570021B2 (en) * 1982-11-22 1988-03-03 Novartis Ag Analogs of mevalolactone
US4472426A (en) * 1982-12-22 1984-09-18 Merck & Co., Inc. Antihypercholesterolemic compounds
PT77996B (en) * 1983-01-24 1986-05-30 Sandoz Sa Process of the preparations of mevalonelactone analogs and derivatives thereof and of pharmaceutical compositions containing them

Also Published As

Publication number Publication date
HUT40398A (en) 1986-12-28
KR910003427B1 (ko) 1991-05-31
DK369086D0 (da) 1986-08-01
EP0216785B1 (fr) 1991-01-30
DK369086A (da) 1986-08-01
JPS62501009A (ja) 1987-04-23
EP0216785A1 (fr) 1987-04-08
HU198005B (en) 1989-07-28
NZ214402A (en) 1989-01-27
PL256608A1 (en) 1988-01-07
AU5230686A (en) 1986-07-01
ES549546A0 (es) 1987-12-01
GR852895B (fr) 1986-04-01
AU599580B2 (en) 1990-07-26
PT81603A (en) 1986-01-01
ATE60571T1 (de) 1991-02-15
PL147645B1 (en) 1989-07-31
FI863121A0 (fi) 1986-07-30
WO1986003488A1 (fr) 1986-06-19
PT81603B (pt) 1988-04-21
KR870700063A (ko) 1987-02-28
IL77199A (en) 1990-02-09
ES8800888A1 (es) 1987-12-01
ZA859303B (en) 1987-07-29
DE3581638D1 (de) 1991-03-07
MY100972A (en) 1991-06-15
FI863121A (fi) 1986-07-30

Similar Documents

Publication Publication Date Title
PH24502A (en) Indene analogs of mevalonolactone and derivatives thereof
GR851510B (fr)
DK165244C (da) Analogifremgangsmaade til fremstilling af 1,2,3-trisubstituerede indoler
ES8604218A1 (es) Un procedimiento para la preparacion de benzoquinolicinas
ES2003086A6 (es) Procedimiento de obtencion de tienoquinolicinsulfonamidas